These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

766 related items for PubMed ID: 15010827

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
    Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, Lichtenstein A.
    Cancer Res; 2002 Sep 01; 62(17):5027-34. PubMed ID: 12208757
    [Abstract] [Full Text] [Related]

  • 3. Determinants of rapamycin sensitivity in breast cancer cells.
    Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F.
    Clin Cancer Res; 2004 Feb 01; 10(3):1013-23. PubMed ID: 14871980
    [Abstract] [Full Text] [Related]

  • 4. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
    Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL.
    Proc Natl Acad Sci U S A; 2001 Aug 28; 98(18):10314-9. PubMed ID: 11504908
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
    Nathan CO, Amirghahari N, Abreo F, Rong X, Caldito G, Jones ML, Zhou H, Smith M, Kimberly D, Glass J.
    Clin Cancer Res; 2004 Sep 01; 10(17):5820-7. PubMed ID: 15355912
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D.
    Clin Cancer Res; 2004 Oct 15; 10(20):6779-88. PubMed ID: 15501954
    [Abstract] [Full Text] [Related]

  • 9. Signaling from Akt to FRAP/TOR targets both 4E-BP and S6K in Drosophila melanogaster.
    Miron M, Lasko P, Sonenberg N.
    Mol Cell Biol; 2003 Dec 15; 23(24):9117-26. PubMed ID: 14645523
    [Abstract] [Full Text] [Related]

  • 10. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
    DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB, Hidalgo M.
    Ann Oncol; 2004 Oct 15; 15(10):1510-6. PubMed ID: 15367412
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
    Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB.
    Proc Natl Acad Sci U S A; 2001 Apr 10; 98(8):4640-5. PubMed ID: 11287630
    [Abstract] [Full Text] [Related]

  • 14. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
    Pene F, Claessens YE, Muller O, Viguié F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D.
    Oncogene; 2002 Sep 26; 21(43):6587-97. PubMed ID: 12242656
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J, Yin M, Zhu Y, Gu L, Zhang Y, Li Q, Jia C, Ma Z.
    BMC Cancer; 2013 Oct 10; 13():471. PubMed ID: 24112608
    [Abstract] [Full Text] [Related]

  • 19. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.
    Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG.
    J Pathol; 2005 Mar 10; 205(4):498-506. PubMed ID: 15714459
    [Abstract] [Full Text] [Related]

  • 20. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X, Jiang BH.
    Am J Physiol Cell Physiol; 2004 Aug 10; 287(2):C281-91. PubMed ID: 15028555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.